Drugs for Neglected Diseases Initiative
Non-profit organization / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Drugs for Neglected Diseases Initiative?
Summarize this article for a 10 year old
The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness (human African trypanosomiasis, HAT), Chagas disease,[1] malaria, filarial diseases, mycetoma, paediatric HIV,[2] cryptococcal meningitis,[3] hepatitis C, and dengue.[4] DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.
Led by Executive Director Luis Pizarro,[5] DNDi has offices in Switzerland (Geneva), Brazil, the Democratic Republic of Congo, India, Japan, Kenya, Malaysia, South Africa, and an affiliate in the United States.